Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.
Department of Pharmacoepidemiology, Norwegian Institute of Public Health, Oslo, Norway.
JAMA Netw Open. 2018 Nov 2;1(7):e184145. doi: 10.1001/jamanetworkopen.2018.4145.
With increasing prevalence of atopic dermatitis (AD) and its manifestation in most countries, together with the supporting evidence of the progression to other atopic phenotypes, AD has developed into a worldwide public health concern. The presence of the disease of has increased since the 1950s, but some recent studies suggest a stationary or decreasing trend.
To analyze a nationwide health register based on prescription data to determine the incidence rate (IR) of AD in an entire pediatric population.
DESIGN, SETTING, AND PARTICIPANTS: All children resident in Norway younger than 6 years from January 1, 2009, through December 31, 2015, were included in this cohort study. Medical diagnoses and disease-specific medications were used as a proxy for identifying children with AD in this population-based prescription registry study. The prescription study was terminated in 2016. The total number of 295 286 disease-specific prescriptions was analyzed from August 2016 through December 2017. The hypothesis was formulated before, during, and after the data collection.
All children with a medical diagnosis of AD or eczema based on at least 2 prescriptions of topical corticosteroids or at least 1 prescription of topical calcineurin inhibitors. Incidence rates per person-year (PY) and IR ratios were calculated.
A total of 295 286 disease-specific prescriptions were dispensed to 122 470 children, of whom 63 460 had AD and 56 009 (88.3%) had reimbursed prescriptions and associated AD diagnoses. The annual Norwegian study population (aged <6 years) increased from 357 451 children in 2009 to 373 954 in 2015. The overall IR increased from 0.028 per PY (95% CI, 0.028-0.029 per PY) in 2009 to 0.034 per PY (95% CI, 0.033-0.035 per PY) in 2014. For children younger than 1 year, the IR increased from 0.052 per PY (95% CI, 0.050-0.053 PY) in 2009 to 0.073 per PY (95% CI, 0.071-0.075 per PY) in 2014. In this age group, the IR was 53% higher in boys compared with girls (IR ratio, 1.53; 95% CI, 1.49-1.57; P < .001). The incidence proportion before the age of 6 years was 17.4% (95% CI, 17.2%-17.7%). The primary seasons for the onset of AD were winter and spring.
This nationwide study suggests an increase in the IR of pediatric AD, especially among children younger than 1 year. This study's findings suggest that increase occurred with a higher IR during winter and spring seasons. Atopic dermatitis had an earlier onset in boys than in girls. During the study period, more than 1 in 6 children younger than 6 years had, at some point, been affected by AD.
随着特应性皮炎(AD)的患病率不断增加,且在大多数国家均有表现,再加上向其他特应性表型进展的证据支持,AD 已经成为全球公共卫生关注的问题。自 20 世纪 50 年代以来,这种疾病的发病率一直在上升,但最近的一些研究表明发病率呈稳定或下降趋势。
分析一项基于处方数据的全国性健康登记处,以确定整个儿科人群中 AD 的发病率(IR)。
设计、设置和参与者:本队列研究纳入了 2009 年 1 月 1 日至 2015 年 12 月 31 日期间居住在挪威、年龄小于 6 岁的所有儿童。本基于处方登记处的研究使用医疗诊断和特定疾病的药物作为识别该人群中 AD 儿童的替代方法。该处方研究于 2016 年结束。从 2016 年 8 月到 2017 年 12 月,分析了 295286 份疾病特异性处方。在数据收集之前、期间和之后提出了假设。
所有至少有 2 次外用皮质类固醇或至少 1 次外用钙调神经磷酸酶抑制剂处方的儿童,都被诊断为 AD 或湿疹。计算了每人数年(PY)的发病率(IR)和 IR 比。
共向 122470 名儿童发放了 295286 份疾病特异性处方,其中 63460 名儿童患有 AD,56009 名(88.3%)有报销处方和相关 AD 诊断。2009 年,挪威每年的研究人群(年龄<6 岁)从 357451 名儿童增加到 2015 年的 373954 名。总体发病率从 2009 年的 0.028/人 PY(95%CI,0.028-0.029/人 PY)增加到 2014 年的 0.034/人 PY(95%CI,0.033-0.035/人 PY)。对于年龄小于 1 岁的儿童,发病率从 2009 年的 0.052/人 PY(95%CI,0.050-0.053 PY)增加到 2014 年的 0.073/人 PY(95%CI,0.071-0.075 PY)。在这个年龄组中,男孩的发病率比女孩高 53%(IR 比,1.53;95%CI,1.49-1.57;P<0.001)。6 岁前的发病比例为 17.4%(95%CI,17.2%-17.7%)。AD 的发病主要季节是冬季和春季。
这项全国性研究表明,儿科 AD 的发病率呈上升趋势,尤其是在 1 岁以下的儿童中。本研究的结果表明,发病率的增加与冬季和春季较高的发病率有关。AD 的发病时间较早,男孩比女孩早。在研究期间,超过 1/6 的 6 岁以下儿童在某个时候曾受到 AD 的影响。